Dennis Ausiello, MD, is a board advisor and member of the PureTech R&D Committee. He is the Jackson Distinguished Professor of Clinical Medicine and was previously director, emeritus of the MD/PhD Program at Harvard Medical School. Dr. Ausiello is chairman of medicine, emeritus and director of the Center for Assessment Technology and Continuous Health (CATCH) at Massachusetts General Hospital (MGH). This center is a partnership among MGH, MIT and Harvard University whose mission is to develop real-time assessment of human traits in wellness and disease. In partnership with industry, it is creating tools for measurements of traditional and novel phenotypes. Understanding the need for partnerships between the academy and industry, Dr. Ausiello served on the board of directors of Pfizer Pharmaceuticals, where he was their former lead director. He currently serves as a member of the board of directors of TARIS, Seres Health and Alnylam. Dr. Ausiello is also a member of the board of directors of several non-public biotech companies and is a consultant to Verily (formerly Google Life Sciences). Dr. Ausiello is a nationally recognized leader in academic medicine who was elected to the National Academy of Medicine in 1999 and the American Academy of Arts and Sciences in 2003. He has published numerous articles, book chapters and textbooks and served as an editor of Cecil's Textbook of Medicine. Dr. Ausiello received his BA from Harvard College and an MD from the University of Pennsylvania.

Raju Kucherlapati, PhD, is an Independent Non-Executive Director at PureTech Health and a member of the R&D Committee. He was a founder and formerly a Board member of Abgenix (acquired by Amgen), and Millennium Pharmaceuticals (acquired by Takeda), and is currently the Paul C. Cabot Professor of Genetics and a Professor of Medicine and at Harvard Medical School. He was the first Scientific Director of the Harvard-Partners Center for Genetics and Genomics. He is a fellow of the American Association for the Advancement of Science and a member of the Institute of Medicine of the National Academy of Sciences. Dr. Kucherlapati’s laboratory at Harvard Medical School is involved in cloning and characterization of human disease genes with a focus on human syndromes with a significant cardiovascular involvement, use of genetic/genomic approaches to understand the biology of cancer and the generation and characterization of genetically modified mouse models for cancer and other human disorders. He served on the editorial board of the New England Journal of Medicine and was Editor in Chief of the journal Genomics.

Robert Langer, ScD, is a co-founder and Non-Executive Director at PureTech Health and sits on PureTech Health's R&D Committee and the Boards of PureTech Health and Entrega. Dr. Langer is known for his groundbreaking discoveries in the fields of polymer chemistry, controlled drug delivery, and tissue engineering. He is the David H. Koch Institute Professor at the Massachusetts Institute of Technology (MIT) and one of 14 Institute Professors (the highest honor awarded to a faculty member). Dr. Langer has written nearly 1,130 articles and has approximately 800 issued or pending patents worldwide, one of which was cited as the outstanding patent in Massachusetts in 1988 and one of 20 outstanding patents in the United States.

His patents have been licensed or sublicensed to over 220 pharmaceutical, chemical, biotech, and medical device companies. Dr. Langer is the most cited engineer in history. He served as a member of the United States FDA’s SCIENCE Board, the FDA’s highest advisory board, from 1995 - 2002 and as its Chairman from 1999 - 2002. Dr. Langer has received over 200 major awards, including the 2006 United States National Medal of Science, the Charles Stark Draper Prize in 2002, considered the equivalent of the Nobel Prize for engineers and the world’s most prestigious engineering prize, and the 2012 Priestley Medal, the highest award of the American Chemical Society. He is also the only engineer to receive the Gairdner Foundation International Award. Among numerous other awards, Dr. Langer has received the Dickson Prize for Science, Heinz Award, the Harvey Prize, the John Fritz Award (given previously to inventors such as Thomas Edison and Orville Wright), the General Motors Kettering Prize for Cancer Research, the Dan David Prize in Materials Science and the Albany Medical Center Prize in Medicine and Biomedical Research. In 2006, he was inducted into the National Inventors Hall of Fame. In 1998, he received the Lemelson-MIT prize, the world’s largest prize for invention for being “one of history’s most prolific inventors in medicine.”

In 1989 Dr. Langer is one of a few people ever elected to all three United States National Academies and is the youngest in history to ever receive this distinction. Discover Magazine, Forbes Magazine and BioWorld have named Dr. Langer as one of the 25 most important individuals in biotechnology in the world. Forbes Magazine selected Dr. Langer as one of the 15 innovators world-wide who will reinvent our future. Time Magazine and CNN named Dr. Langer as one of the 100 most important people in America and one of the 18 top people in science or medicine in America. Dr. Langer has served, at various times, on the Boards of such companies as Wyeth, Alkermes, Mitsubishi Pharmaceuticals, Warner-Lambert, Millipore, and Momenta Pharmaceuticals.

Dame Marjorie Scardino is the Senior Independent Director of PureTech Health’s Board of Directors. She served as Chief Executive of The Economist for 12 years and then from 1997 through 2012 was the Chief Executive of Pearson plc, the world's leading education company and the owner of Penguin Books and The Financial Times Group. She is currently the Chairman of The MacArthur Foundation and is also a member of the non-profit boards of Oxfam, The Royal College of Art, and The Carter Center, as well as the for-profit boards of Twitter, where she sits on the audit committee, and IAG (the holding company of British Airways, Iberia and other airlines). Dame Marjorie has received a number of honorary degrees, and in 2003 was dubbed a Dame of the British Empire. She is also a member of the Royal Society of the Arts in the UK and the American Association of Arts and Sciences.

Christopher Viehbacher is the Managing Partner of Gurnet Point Capital. He is also the Chairman of the Board of Directors of Boston Pharmaceuticals and of Vedanta Biosciences as well as the Vice-Chair of Nuvelution. He is a member of the Board of Directors of Pronutria. Mr. Viehbacher is a Trustee of Northeastern University and the Past-Chair of the CEO Roundtable on Cancer.

Mr. Viehbacher is the former CEO of Sanofi, a Paris listed Fortune 50 Biopharmaceutical Company and the former Chairman of Genzyme. During his six year tenure, Sanofi underwent a significant business transformation, completing over $30 billion of acquisitions, most notably, Genzyme Ltd. Prior to joining Sanofi, Mr Viehbacher spent 20 years at GlaxoSmithKline, ultimately serving as President of GSK’s North American pharmaceutical division and as a member of the Board of Directors of GSK plc. He began his career with PriceWaterhouseCoopers LLP and qualified as a Chartered Accountant in Canada.

Mr. Viehbacher has co-chaired the CEO Roundtable on Neglected Diseases with Bill Gates, an organization that led to over 1.3 billion people being treated for such diseases free of charge. He was the Chairman of the Board of the Pharmaceutical Research and Manufacturers of America (PhRMA) as well as President of the European Federation of Pharmaceutical Industries and Associations (EFPIA). At the World Economic Forum at Davos, he was a Chair of the Health Governors and co-chaired an initiative to create a Global Charter for Healthy Living. He was also a member of the International Business Council. Mr. Viehbacher has received the Pasteur Foundation Award for outstanding commitment to safeguarding and improving health worldwide. He has also received France’s highest civilian honor, the Legion d’Honneur. Various awards form the Thompson Reuters/Excel Investor Survey, including top Chief Executive Officer and top European company, have recognized his commitment to investor relations.